Monog.M'd.- 12 CASTELLË filmar2 - Acadèmia

EL FUTURO DE LA FARMACOLOGÍA ANALGÉSICA:MÁS ALLÁ DE LOS OPIOIDES Y DE LOS AINE 277Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoidreceptor and functional expression of the cloned cDNA. Nature 1990;346:561-564.Max MB. Is mechanism-based pain treatment attainable? Clinical trial issues. JPain 2000; 1 (suppl.1): 2-9.Meldrum BS. Possible therapeutic applications of antagonists of excitatoryamino acid neurotransmitters. Clin Sci 1985; 68: 113-122.Melzack R, Wall PD. Pain mechanisms: a new theory. Science 1965; 150:971-979.Neugebauer V, Kornhuber J, Lucke T, Schaible HG. The clinically availableNMDA receptor antagonist memantine is antinociceptive on rat spinal neurones.Neuroreport 1993; 4: 1259-1262.Noyes R, Brunk, Avery DH, Canter A. The analgesic properties of delta-9-tetrahydro cannabinol and codeine. Clin Pharmacol Ther 1975; 18:84-89.Olney JW. Excitotoxic amino-acids and neuropsychiatric disorders. Ann RevPharm Toxicol 1990; 30: 47-71.Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: Evidencefor a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 1992; 260:1209-1213.Ossipov MH, Lai J, Malan TP, Porreca F. Recent advances in the pharmacology ofopioides. En Sawynok J, Cowan A (eds.) Novel aspects of pain management.Opioids and beyond. John Wiley & Sons: Nueva York, 1999; 49-72.Parsons CG. NMDA receptors as targets for drug action in neuropathic pain. EurJ Pharmacol 2001; 429: 71-78.Perkins MN, Campbell E, Dray A. Antinociceptive activity of the bradykinin B 1and B 2 receptor antagonists, desArg 9 (Leu 8 )-Bk and HOE 140, in tow models ofpersistent hyperalgesia in the rat. Pain 1993; 53: 191-197.Petersson J, Gordh TE, Hartvig P, Wiklund L. A double-blind trial of the analgesicproperties of physostigmine in postoperative patients. Acta AnaesthesiolScand 1986; 30: 283-288.Picard PR, Tramer MR, McQuay HJ, Moore RA. Analgesic efficacy of peripheralopioids (all except intra-articular): a qualitative systematic review of randomisedcontrolled trials. Pain 1997; 72:309-318.Planells-Cases R, Aracil A, Merino JM, Gallar J, Pérez-Payá E, Belmonte C,González JM, Ferrer-Montiel AV. Arginine-rich peptides are blockers of VR-1channels with analgesic activity. FEBS Letters 2000; 481: 131-136.Rang HP, Bevan SJ, Perkins MH. Peripherally acting analgesic agents. EnSawynok J, Cowan A (eds.) Novel aspects of pain management. Opioids andbeyond. John Wiley & Sons: Nueva York, 1999; 95-115.Richardson JD. Cannabinoids modulate pain by multiple mechanisms of action.J Pain 2000; 1: 2-14.Rupniak NJ, Hill RG. Neurokinin antagonists. En Sawynok J, Cowan A. Novel aspectsof pain management: opioids and beyond. Wiley-Liss: Nueva York, 1999; 135-155.Sánchez A, Niebbala B, Feria M. Modulation of neuropathic pain in rats byintrathecally injected serotonergic agonists. Neuroreport 1995; 6:2585-2588.Sawynok J, Sweeney MI, White TD. Classification of adenosine receptors mediatingantinociception in the rat spinal cord. Br J Pharmacol 1986; 88: 923-930.